These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 25261710

  • 21. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D, Harder A, Fang Z, Weinheimer M, Laplanche L, Mezler M.
    Pharm Res; 2020 Sep 11; 37(10):194. PubMed ID: 32918191
    [Abstract] [Full Text] [Related]

  • 22. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells.
    Fan J, Maeng HJ, Du Y, Kwan D, Pang KS.
    Eur J Pharm Sci; 2011 Jan 18; 42(1-2):19-29. PubMed ID: 20955791
    [Abstract] [Full Text] [Related]

  • 23. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
    Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Liu PQ, Duan W, Chowbay B, Wen JY, Li CG, Zhou SF.
    Curr Drug Metab; 2007 May 18; 8(4):325-40. PubMed ID: 17504222
    [Abstract] [Full Text] [Related]

  • 24. Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.
    Vadlapatla RK, Vadlapudi AD, Kwatra D, Pal D, Mitra AK.
    Int J Pharm; 2011 Nov 25; 420(1):26-33. PubMed ID: 21864659
    [Abstract] [Full Text] [Related]

  • 25. Prodrug approach to improve absorption of prednisolone.
    Sheng Y, Yang X, Pal D, Mitra AK.
    Int J Pharm; 2015 Jun 20; 487(1-2):242-9. PubMed ID: 25888804
    [Abstract] [Full Text] [Related]

  • 26. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
    Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK.
    Int J Pharm; 2010 Aug 16; 395(1-2):114-21. PubMed ID: 20573570
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
    Karyekar CS, Eddington ND, Garimella TS, Gubbins PO, Dowling TC.
    Pharmacotherapy; 2003 Apr 16; 23(4):436-42. PubMed ID: 12680473
    [Abstract] [Full Text] [Related]

  • 29. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
    Zhu X, Zhang X, Ma G, Yan J, Wang H, Yang Q.
    J Pharm Pharm Sci; 2011 Apr 16; 14(3):325-35. PubMed ID: 21824448
    [Abstract] [Full Text] [Related]

  • 30. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.
    Su Y, Zhang X, Sinko PJ.
    Mol Pharm; 2004 Jan 12; 1(1):49-56. PubMed ID: 15832500
    [Abstract] [Full Text] [Related]

  • 31. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.
    Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
    Ouyang H, Tang F, Siahaan TJ, Borchardt RT.
    Pharm Res; 2002 Jun 15; 19(6):794-801. PubMed ID: 12134949
    [Abstract] [Full Text] [Related]

  • 34. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
    Dahan A, Sabit H, Amidon GL.
    AAPS J; 2009 Jun 15; 11(2):205-13. PubMed ID: 19319690
    [Abstract] [Full Text] [Related]

  • 35. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
    Guo A, Marinaro W, Hu P, Sinko PJ.
    Drug Metab Dispos; 2002 Apr 15; 30(4):457-63. PubMed ID: 11901101
    [Abstract] [Full Text] [Related]

  • 36. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
    Udomnilobol U, Jianmongkol S, Prueksaritanont T.
    Drug Metab Dispos; 2023 Sep 15; 51(9):1216-1226. PubMed ID: 37230768
    [Abstract] [Full Text] [Related]

  • 37. Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes.
    Anger GJ, Piquette-Miller M.
    Drug Metab Dispos; 2011 Oct 15; 39(10):1850-9. PubMed ID: 21742899
    [Abstract] [Full Text] [Related]

  • 38. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
    Patel J, Hussain A, Pal D, Mitra AK.
    Am J Ther; 2004 Oct 15; 11(2):114-23. PubMed ID: 14999363
    [Abstract] [Full Text] [Related]

  • 39. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
    Lagas JS, Damen CW, van Waterschoot RA, Iusuf D, Beijnen JH, Schinkel AH.
    Mol Pharmacol; 2012 Oct 15; 82(4):636-44. PubMed ID: 22767610
    [Abstract] [Full Text] [Related]

  • 40. Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator.
    Choi MK, Kwon M, Ahn JH, Kim NJ, Bae MA, Song IS.
    Biopharm Drug Dispos; 2014 Apr 15; 35(3):183-94. PubMed ID: 24285344
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.